OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.057
EU - Europa 4.846
AS - Asia 3.768
SA - Sud America 587
AF - Africa 99
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 12
Totale 17.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.938
IT - Italia 1.296
CN - Cina 1.177
SG - Singapore 1.076
GB - Regno Unito 907
IE - Irlanda 830
HK - Hong Kong 552
BR - Brasile 473
DE - Germania 468
SE - Svezia 364
VN - Vietnam 252
RU - Federazione Russa 202
FR - Francia 168
ID - Indonesia 133
FI - Finlandia 121
IN - India 103
UA - Ucraina 103
TR - Turchia 83
KR - Corea 76
CA - Canada 65
BG - Bulgaria 60
JP - Giappone 52
AR - Argentina 46
NL - Olanda 45
LT - Lituania 42
PL - Polonia 42
IQ - Iraq 40
TW - Taiwan 39
MX - Messico 32
BD - Bangladesh 29
BE - Belgio 29
CZ - Repubblica Ceca 28
ES - Italia 28
AU - Australia 27
EG - Egitto 26
MY - Malesia 24
IR - Iran 23
ZA - Sudafrica 23
AT - Austria 22
PK - Pakistan 20
CL - Cile 17
EC - Ecuador 17
CO - Colombia 15
RO - Romania 15
MD - Moldavia 12
CH - Svizzera 11
VE - Venezuela 11
EU - Europa 10
KE - Kenya 9
PH - Filippine 9
MA - Marocco 8
IL - Israele 7
SA - Arabia Saudita 7
TN - Tunisia 7
DO - Repubblica Dominicana 6
GR - Grecia 6
HU - Ungheria 6
NP - Nepal 6
TH - Thailandia 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
GH - Ghana 5
MT - Malta 5
RS - Serbia 5
AL - Albania 4
CR - Costa Rica 4
HN - Honduras 4
LB - Libano 4
NG - Nigeria 4
NO - Norvegia 4
PE - Perù 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
IS - Islanda 3
JO - Giordania 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LV - Lettonia 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
BW - Botswana 2
CY - Cipro 2
DK - Danimarca 2
ET - Etiopia 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
PY - Paraguay 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
Totale 17.375
Salva come PNG Salva come JPEG
Città #
Santa Clara 959
Ashburn 845
Dublin 826
Singapore 723
Fairfield 636
Chandler 592
Hong Kong 534
Dallas 470
Southend 420
Hefei 337
Houston 295
Woodbridge 294
Nyköping 259
Seattle 254
Wilmington 240
Ann Arbor 227
Dearborn 215
Beijing 213
London 205
Cambridge 176
New York 165
Jacksonville 144
Los Angeles 144
Modena 141
Chicago 112
Jakarta 108
Munich 107
Shanghai 91
Milan 87
Helsinki 86
Ho Chi Minh City 83
The Dalles 76
San Diego 74
Moscow 71
Bologna 69
Seoul 68
Fremont 62
Rome 61
Princeton 60
Sofia 60
Redwood City 52
Council Bluffs 46
Hanoi 46
Eugene 44
Dong Ket 41
São Paulo 41
Frankfurt am Main 40
Izmir 37
Tokyo 36
Salt Lake City 35
Bremen 33
Buffalo 32
Enfield 32
Warsaw 32
Guangzhou 31
Lauterbourg 30
Reggio Emilia 30
Columbus 29
Phoenix 28
Baghdad 27
Parma 27
San Giuliano Milanese 26
Elk Grove Village 25
Falls Church 25
Portsmouth 24
Redondo Beach 24
Paris 23
Lawrence 22
Asyut 21
Brooklyn 21
Brussels 21
Tampa 21
Nuremberg 20
Kent 18
Orem 18
Toronto 17
Turku 17
Brno 15
Düsseldorf 15
Poplar 15
Atlanta 14
Banqiao 14
Boardman 14
Denver 14
Absecon 13
Belo Horizonte 13
Genoa 13
Mexico City 13
Mumbai 13
Porto Alegre 13
Amsterdam 12
Boston 12
Chisinau 12
Des Moines 12
Nanjing 12
Norwalk 12
Ottawa 12
Palermo 12
Johannesburg 11
Montreal 11
Totale 11.978
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 515
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 379
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 360
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 351
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 350
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 319
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 316
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 316
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 313
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 309
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 308
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 301
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 294
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 287
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 279
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 277
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 277
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 277
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 268
Immune characterization of breast cancer metastases: prognostic implications. 263
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 262
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 260
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 256
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 254
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 250
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 249
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 247
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 247
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 245
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 240
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 239
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 234
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 225
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 224
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 221
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 220
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 217
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 217
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 215
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 210
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 208
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 208
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 207
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 202
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 201
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 201
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 201
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 197
The role of exosomes in breast cancer diagnosis 190
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 185
Lapatinib and renal impairment: a case report 183
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 180
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 180
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 180
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 178
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 178
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 170
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 168
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 168
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 168
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 167
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 166
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 165
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 154
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 151
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 148
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 142
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 130
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 127
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 126
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 122
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 121
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 116
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 115
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 115
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 109
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 106
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 101
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 87
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 85
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 82
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 62
Totale 17.541
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.531
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.531
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021959 0 0 0 0 0 129 70 180 102 195 124 159
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20254.164 141 53 127 268 814 592 319 257 410 286 335 562
2025/20263.772 567 251 924 798 1.108 124 0 0 0 0 0 0
Totale 17.541